CognitiveIn Clinical Trials

Intranasal Insulin

Intranasal

Overview

Intranasal insulin involves the administration of regular human insulin via nasal spray to target central nervous system insulin receptors without causing systemic hypoglycemia. Insulin signaling in the brain is implicated in synaptic plasticity, glucose metabolism, and amyloid clearance, providing a rationale for cognitive enhancement in insulin-resistant states and Alzheimer disease.

Mechanism of Action

Intranasal delivery bypasses the blood-brain barrier via olfactory and trigeminal nerve pathways..

Research Summary & Key Findings

Multiple phase II trials have evaluated intranasal insulin in mild cognitive impairment and early Alzheimer disease, with some studies reporting modest improvements in memory and executive function. A large multicenter trial is ongoing, and prior smaller studies have been published in journals including Neurology and the Journal of Alzheimer's Disease over the past decade.

Clinical Status

In Clinical Trials

Intranasal Insulin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Intranasal

Related Peptides in Cognitive

Find a Provider

Find a verified provider who offers Intranasal Insulin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Intranasal Insulin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.